KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Invested Capital (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Invested Capital readings, the most recent being -$116.4 million for Q4 2025.

  • On a quarterly basis, Invested Capital rose 75.34% to -$116.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$116.4 million, a 75.34% increase, with the full-year FY2025 number at -$116.4 million, up 75.34% from a year prior.
  • Invested Capital hit -$116.4 million in Q4 2025 for Biocryst Pharmaceuticals, up from -$384.7 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $191.2 million in Q4 2021 to a low of -$472.0 million in Q1 2024.
  • Median Invested Capital over the past 5 years was -$220.1 million (2022), compared with a mean of -$243.2 million.
  • Biggest five-year swings in Invested Capital: soared 93.01% in 2022 and later plummeted 3896.75% in 2023.
  • Biocryst Pharmaceuticals' Invested Capital stood at $191.2 million in 2021, then tumbled by 252.74% to -$292.0 million in 2022, then plummeted by 54.5% to -$451.1 million in 2023, then fell by 4.63% to -$472.0 million in 2024, then surged by 75.34% to -$116.4 million in 2025.
  • The last three reported values for Invested Capital were -$116.4 million (Q4 2025), -$384.7 million (Q3 2025), and -$417.9 million (Q2 2025) per Business Quant data.